ArticleAlzheimer's & dementia (New York, N. Y.)
Uptake of tau-PET and neuropathological and autoradiographic findings from a globular glial tauopathy case series.
Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionGlobular glial tauopathy (GGT) is a rare type of frontotemporal lobar degeneration (FTLD) characterized by deposition of 4-repeat tau. Detecting GGT with tau positron emission tomography (tau-PET) is challenging. We aim to determine the associations between tau-PET, autoradiography, and neuropathology methods in GGT.
methodsWe identified three patients with GGT who had completed antemortem tau-PET. Healthy control and two patients with Alzheimer's disease (AD) were also included for comparison. We analyzed gray matter (GM) and white matter (WM) from the superior/middle frontal gyrus (S/M-FG) and the superior/middle temporal gyrus (S/M-TG). Immunohistochemical staining was performed with antibodies against phospho-tau (AT8, PHF-1, RD4), glial fibrillary acidic protein (GFAP), and resting microglia (ionized calcium-binding adaptor molecule 1; Iba1). Immunofluorescence with a fluorescent tau-PET analog (T726) was performed. Regional tau-PET standardized uptake value ratios (SUVRs) were calculated for comparative GM and WM regions. Autoradiographic studies with 18F-AV1451 were also conducted.
resultsTau-PET showed increased uptake in the WM regions of the S/M-FG and S/M-TG in GGT, and the GM regions in AD. Co-localization was observed between T726 and PHF-1, RD4, and GFAP in the WM in the patients with GGT, whereas co-localization was observed with PHF-1 predominantly in the GM in AD. Little co-localization was observed with Iba1. In vitro 18F-AV1451 autoradiography studies demonstrated minimal binding in GGT. Tau-PET differentiated underlying GGT from AD based on the relative involvement of the WM and GM.
conclusionHistopathologic findings suggest that some flortaucipir uptake in GGT may represent underlying 4R tau, whereas autoradiographic analysis suggests that uptake is likely due to off-target binding. Further studies with larger cohorts are needed to determine the pathological basis of flortaucipir uptake in GGT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.